Gastrointestinal stromal tumor (GIST) — the most common mesenchymal tumor of the gastrointestinal tract, arising from the interstitial cells of Cajal (the pacemaker cells of the GI tract) or their precursors and accounting for approximately 4,000–6,000 new cases diagnosed annually in the United States, with the stomach (50–60% of cases) and small intestine (25–30%) representing the predominant anatomic sites followed by the rectum (5%), esophagus (<2%), and mesentery or omentum (rare extraintestinal presentations) — is the paradigmatic molecularly driven sarcoma and the disease whose oncology established the proof of concept for receptor tyrosine kinase inhibitor therapy in solid tumors through imatinib's dramatic response rates in KIT-mutant GIST when first reported in 2001. GISTs are classified by their driving molecular alteration into five major subgroups: KIT-mutant GIST (approximately 75–80% of all GISTs, with exon 11 mutations — in-frame deletions, point mutations, or duplications in the KIT juxtamembrane domain — representing the most common and imatinib-responsive subset in approximately 65% of all GISTs, and exon 9 mutations — associated with small intestinal location and requiring high-dose imatinib 800 mg/day for optimal response — in approximately 10% of all GISTs), PDGFRA-mutant GIST (approximately 8–10% of all GISTs, predominantly in the stomach, with PDGFRA exon 18 D842V mutation representing approximately 5–6% of all GISTs and critically imatinib-resistant, now addressed by avapritinib — the first treatment-approved drug specifically targeting PDGFRA D842V-mutant GIST with an 84% objective response rate), SDH-deficient GIST (approximately 5–7%, occurring predominantly in children and young adults, associated with gastric location, multifocal disease, and the Carney triad and Carney-Stratakis syndrome, driven by somatic or germline mutations in SDHA, SDHB, SDHC, or SDHD with loss of SDH protein expression by immunohistochemistry, and KIT/PDGFRA-negative and imatinib-insensitive), NF1-associated GIST (approximately 1–2%, occurring in neurofibromatosis type 1 patients, KIT and PDGFRA wild-type, predominantly in the small intestine, multifocal, and with an indolent biology despite imatinib insensitivity), and BRAF-mutant or other rare molecular subtypes (<1% each). The treatment paradigm for localized, surgically resectable GIST is complete gross resection (R0) without routine lymph node dissection (lymph node metastasis being vanishingly rare in GIST in contrast to most carcinomas), followed by adjuvant imatinib for KIT or PDGFRA-mutant (non-D842V) high-risk patients — as defined by tumor size, mitotic rate, and primary site using the modified NIH or Armed Forces Institute of Pathology risk stratification schemes — for 3 years based on the ACOSOG Z9001 and SSG XVIII trials demonstrating improved recurrence-free and overall survival. Metastatic or unresectable GIST is treated with sequential tyrosine kinase inhibitor therapy: imatinib first-line (400 mg/day for exon 11 KIT-mutant, 800 mg/day for exon 9 KIT-mutant), sunitinib second-line (for imatinib-refractory or intolerant disease, with 4-2 on/off schedule or continuous 37.5 mg/day dosing), regorafenib third-line, ripretinib fourth-line, and avapritinib for PDGFRA D842V-mutant GIST at any line. Surgical oncologists performing laparoscopic or open gastric and small intestinal GIST resection, GI medical oncologists managing imatinib dose titration and adverse effect surveillance, oncology pharmacists monitoring tyrosine kinase inhibitor drug-drug interactions, molecular pathologists performing KIT and PDGFRA mutation genotyping by Sanger sequencing or NGS (critical for avapritinib eligibility and imatinib dose selection), and investigators coordinating enrollment in ripretinib combination trials, bezuclastinib trials (for PDGFRA D842V variants), and SDH-deficient GIST immunotherapy studies all coordinate care across one of the most molecularly stratified and continuously evolving targeted therapy landscapes in solid tumor oncology.
GIST technology platforms — whether supporting surgical oncology programs coordinating laparoscopic or open gastrectomy, small bowel resection, or rectal GIST resection with restoration of GI continuity, adjuvant imatinib programs managing 3-year post-resection imatinib therapy with active adverse effect surveillance (edema, fatigue, nausea, myelosuppression, QTc prolongation) and risk stratification documentation, metastatic GIST programs coordinating imatinib dose escalation and response assessment (RECIST 1.1 and Choi criteria CT-based response assessment), sunitinib programs managing the dose-limiting toxicities of hand-foot skin reaction (HFSR), hypertension, hepatotoxicity, and thyroid function suppression requiring active cardiovascular and endocrine monitoring, regorafenib programs managing HFSR, hepatotoxicity, hypertension, and cardiovascular event surveillance (regorafenib carries heightened hepatotoxicity warnings requiring active liver function monitoring), ripretinib programs managing HFSR and alopecia, avapritinib programs managing the unique avapritinib adverse effect profile including intracranial hemorrhage risk (requiring platelet monitoring), cognitive effects and memory impairment (requiring patient-reported outcome documentation), and periorbital edema, molecular genotyping programs performing KIT exon 11, 9, 13, 17 and PDGFRA exon 12, 14, 18 mutation testing (and SDHA/B/C/D IHC for SDH-deficient GIST subtyping), clinical trial programs enrolling patients in next-generation kinase inhibitor, immunotherapy (for SDH-deficient GIST), or combination TKI studies, or patient portals supporting GIST patients and families managing long-term (years to decades) tyrosine kinase inhibitor therapy with complex toxicity profiles and multi-year surveillance imaging programs — must maintain the availability and performance standards that GIST's molecular precision, long-duration TKI therapy management, sequential kinase inhibitor adverse effect monitoring, and response assessment requirements demand. This guide explains why GIST tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the molecularly stratified TKI therapy management, surgical coordination, and long-duration surveillance of modern GIST care.
Why GIST Tech Platforms Require Specialized Monitoring Attention
GIST management is defined by KIT and PDGFRA molecular genotyping for treatment selection and imatinib dose determination, sequential TKI therapy through multiple lines (imatinib → sunitinib → regorafenib → ripretinib, with avapritinib for PDGFRA D842V), active adverse effect surveillance for each TKI's toxicity profile, surgical coordination for resectable primary and oligometastatic disease, response assessment by RECIST and Choi criteria, and long-term adjuvant imatinib management. Technology failures in any of these areas create disruptions calibrated to the molecular precision and continuous TKI management requirements unique to GIST.
KIT and PDGFRA molecular genotyping platforms drive imatinib dose selection and avapritinib eligibility. KIT exon 11 mutation confirmation — by Sanger sequencing or NGS — establishes imatinib 400 mg/day as the appropriate first-line dose and excludes exon 9 mutation status, which requires imatinib 800 mg/day for adequate target inhibition. PDGFRA exon 18 D842V mutation confirmation — the imatinib-resistant variant present in approximately 5–6% of all GISTs — is required to establish avapritinib eligibility in both the metastatic and adjuvant settings. SDH protein IHC (SDHA/SDHB loss) is required to diagnose SDH-deficient GIST and guide management decisions including avoidance of TKI therapy. Platforms managing molecular test ordering, genotyping result routing, mutation classification documentation, and clinical trial eligibility records cannot fail during active diagnostic and treatment initiation windows. Monitor molecular genotyping platforms at 1-minute intervals during business hours.
Imatinib management platforms coordinate long-duration adjuvant and metastatic therapy. Adjuvant imatinib — delivered for 3 years post-resection in high-risk KIT or PDGFRA (non-D842V) mutant GIST — requires platforms managing daily dosing compliance records, adverse effect surveillance (edema, nausea, fatigue, myelosuppression, QTc monitoring for cardiac risk patients), CBC and metabolic panel monitoring scheduling, dose modification documentation, and annual chest and abdominal CT surveillance. Metastatic imatinib management requires active response assessment (CT-based RECIST and Choi criteria) and imatinib resistance monitoring (progression on therapy triggering sunitinib transition). Monitor imatinib management platforms at 1-minute intervals during business hours.
Sunitinib management platforms require active cardiovascular and endocrine monitoring. Sunitinib second-line therapy for imatinib-refractory GIST carries a toxicity profile requiring active surveillance: hand-foot skin reaction (HFSR) grading and dose modification, hypertension management (affecting 17–34% of patients, sometimes requiring antihypertensive initiation), thyroid function suppression (hypothyroidism in 36–85% of patients on prolonged sunitinib, requiring TSH monitoring and thyroid hormone replacement), hepatotoxicity surveillance, left ventricular ejection fraction monitoring, and QTc prolongation surveillance. Platforms managing these monitoring protocols, dose modification documentation, and concurrent antihypertensive and thyroid replacement coordination cannot fail during active sunitinib cycles. Monitor sunitinib management platforms at 1-minute intervals during business hours.
Regorafenib management platforms monitor hepatotoxicity risk. Regorafenib third-line therapy for GIST carries an FDA boxed warning for severe hepatotoxicity (Grade 3–4 liver injury occurring in approximately 1.5% of patients across clinical trials, with fatal hepatic failure documented). Platforms managing ALT/AST monitoring scheduling and result routing, dose interruption and reduction documentation for hepatotoxicity, HFSR and fatigue grading, hypertension surveillance, bilirubin monitoring, and drug interaction documentation (regorafenib is a strong CYP3A4 inducer) cannot fail during active regorafenib therapy. Monitor regorafenib management platforms at 1-minute intervals during business hours with elevated alerting sensitivity during hepatotoxicity monitoring windows.
Avapritinib management platforms require intracranial hemorrhage and cognitive monitoring. Avapritinib — the only approved therapy for PDGFRA D842V-mutant GIST and active in fourth-line KIT-mutant GIST — carries a unique adverse effect profile including intracranial hemorrhage risk (particularly in patients with intracranial GIST metastases, requiring platelet count monitoring before each cycle and avoidance in patients with active CNS metastases), cognitive effects (memory impairment, cognitive slowing, and dizziness occurring in approximately 40% of patients), and periorbital and facial edema. Platforms managing platelet count surveillance before each avapritinib cycle, patient-reported cognitive outcome documentation, edema grading records, and dose modification documentation for cognitive adverse effects cannot fail during active avapritinib therapy. Monitor avapritinib management platforms at 1-minute intervals during business hours.
GIST surgical planning platforms coordinate laparoscopic and open resection. Surgical resection for localized GIST — laparoscopic gastric wedge resection for most gastric GISTs ≤5 cm, open resection for large or complex gastric GISTs, small bowel resection for jejunal or ileal GISTs, low anterior resection for rectal GISTs — requires platforms managing pre-operative imaging records (CT and endoscopic ultrasound documentation), operative planning records, laparoscopic port placement documentation, intraoperative pathology routing, and post-operative complication surveillance. Monitor surgical planning platforms at 1-minute intervals during business hours and operative windows.
What to Monitor on a GIST Tech Platform
KIT and PDGFRA Molecular Genotyping
Monitor KIT exon 11, 9, 13, 17 and PDGFRA exon 12, 14, 18 mutation test ordering and result routing, PDGFRA D842V confirmation and avapritinib eligibility documentation, SDH protein IHC (SDHA/SDHB) result routing, NGS panel result access, risk stratification documentation, and clinical trial eligibility records at 1-minute intervals during business hours. Alert immediately — molecular genotyping access failures delay imatinib dose selection and avapritinib eligibility determination in a disease where the wrong dose or wrong drug agent can mean inadequate tumor control from the start of therapy.
Imatinib Adjuvant and Metastatic Management
Monitor imatinib dosing and compliance records, CBC and metabolic panel monitoring scheduling and results, QTc surveillance documentation, edema and GI toxicity grading records, dose modification documentation, annual adjuvant surveillance CT scheduling and reporting, and RECIST/Choi criteria response assessment records at 1-minute intervals during business hours. Alert immediately — imatinib management platform failures delay toxicity monitoring and response assessment in a therapy measured across years.
Sunitinib Management and Cardiovascular Monitoring
Monitor sunitinib dosing schedule (4-2 or continuous) and cycle records, HFSR grading and dose modification documentation, hypertension surveillance and antihypertensive management records, TSH monitoring and thyroid hormone replacement documentation, LVEF monitoring scheduling and cardiac function records, hepatotoxicity surveillance (ALT/AST), QTc prolongation documentation, and response assessment CT records at 1-minute intervals during business hours. Alert immediately — sunitinib toxicity management requires real-time access to cardiovascular and endocrine monitoring records.
Regorafenib Management and Hepatotoxicity Surveillance
Monitor ALT/AST monitoring scheduling and result routing during active regorafenib therapy, dose interruption and reduction documentation for hepatotoxicity, HFSR grading records, bilirubin monitoring, hypertension surveillance, fatigue grading, drug interaction documentation, and response assessment records at 1-minute intervals during business hours. Alert immediately — regorafenib hepatotoxicity monitoring is time-sensitive given the severity risk and FDA boxed warning.
Avapritinib Management and Neurological Safety Monitoring
Monitor platelet count surveillance before each avapritinib cycle, intracranial hemorrhage risk documentation, patient-reported cognitive outcome records (memory, dizziness, cognitive slowing), periorbital edema grading, dose modification documentation for cognitive adverse effects, CNS GIST metastasis surveillance imaging, and response assessment records at 1-minute intervals during business hours. Alert immediately — avapritinib platelet monitoring failures carry intracranial hemorrhage risk.
Ripretinib Management
Monitor ripretinib dosing records, HFSR grading and dose modification documentation, alopecia and fatigue management records, response assessment CT records, and transition to next-line therapy documentation at 1-minute intervals during business hours. Alert immediately — ripretinib management failures affect patients in the fourth line of therapy with very limited subsequent options.
GIST Surgical Planning and Resection
Monitor pre-operative CT and EUS imaging records, laparoscopic vs. open resection planning documentation, intraoperative pathology routing (frozen sections confirming negative margins), post-operative complication surveillance, adjuvant imatinib initiation coordination, and post-surgical surveillance CT scheduling at 1-minute intervals during business hours and operative windows. Alert immediately during active operative and perioperative windows.
CT and MRI Response Assessment (RECIST and Choi Criteria)
Monitor response assessment CT scheduling and result routing for active TKI therapy monitoring, Choi criteria documentation (density-based response assessment critical in GIST where lesions may increase in size while responding to imatinib through myxoid degeneration), PET/CT scanning for equivocal CT response cases, and radiologic progression documentation triggering line-change decisions at 1-minute intervals during business hours. Alert immediately — response assessment access failures delay progression detection and TKI transition decisions.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. GIST programs coordinate across surgical oncology, GI medical oncology, oncology pharmacy (for TKI drug-drug interaction management), cardiology (sunitinib LVEF monitoring), endocrinology (sunitinib thyroid management), radiology, and molecular pathology — authentication failures simultaneously block every member of a care team managing patients on long-duration sequential TKI therapy where molecular genotyping records, sequential toxicity surveillance, and multi-line response assessment require continuous coordinated platform access.
SSL Certificates Across All Domains
Monitor SSL certificate expiry across all patient portals, surgical planning systems, TKI management platforms, molecular genotyping interfaces, cardiovascular monitoring systems, response assessment platforms, and clinical trial management tools. Certificate errors disrupt the long-duration TKI management and molecular diagnostic workflows central to GIST care.
HIPAA and Oncology Data Privacy Considerations
GIST technology platforms handle sensitive PHI including KIT and PDGFRA molecular genotyping records (with implications for germline testing in PDGFRA or SDH-deficient GIST with familial syndrome associations such as Carney-Stratakis syndrome), avapritinib cognitive adverse effect and neurological monitoring records, sunitinib cardiovascular monitoring records including LVEF measurements and antihypertensive prescription data, regorafenib hepatotoxicity records with liver failure risk documentation, long-duration imatinib compliance and response records spanning years of continuous therapy, SDHA/SDHB germline mutation records that implicate familial cancer syndrome risk to relatives, and clinical trial enrollment data in a patient population where multi-line TKI therapy may span a decade or more. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components, with heightened sensitivity for germline SDH mutation records that have familial implications extending beyond the index patient.
For platforms managing avapritinib intracranial hemorrhage risk monitoring records — where platelet count access before each cycle directly prevents a potentially fatal adverse event — data availability standards must reflect the patient safety criticality of pre-treatment safety checks. For platforms managing sunitinib LVEF monitoring records in patients with pre-existing cardiovascular risk, availability standards must match the cardiac surveillance dependency. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for GIST programs managing oncology PHI across long-duration, multi-line TKI therapy phases.
Alerting Strategy for GIST Tech Platforms
Immediate alerting 24/7: Authentication and core platform access. GIST patients on active TKI therapy may experience urgent toxicity events (hypertensive crisis on sunitinib, severe hepatotoxicity on regorafenib) requiring care team access outside business hours.
Immediate alerting during treatment initiation and monitoring sessions: Imatinib management during active dose modification and toxicity monitoring; sunitinib cardiovascular and endocrine monitoring during active cycle surveillance; regorafenib hepatotoxicity surveillance during the first 8 weeks of treatment when hepatic risk is highest; avapritinib platelet and cognitive monitoring before each treatment cycle. These monitoring platforms cannot fail during active safety surveillance.
Immediate business-hours alert: KIT and PDGFRA molecular genotyping (treatment selection and dose determination), CT/MRI response assessment (progression detection and line-change decisions), GIST surgical planning (during operative windows), ripretinib management, and clinical trial coordination. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Patient communication portal, long-duration adjuvant imatinib surveillance scheduling, thyroid replacement management documentation, and late surveillance imaging. Alert when failures persist beyond a single workflow cycle.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms GIST platform availability from the geographies where sarcoma specialist centers, GI oncology programs, molecular genotyping laboratories, and TKI management infusion suites access the system — important for platforms supporting GIST patients who may travel to specialist centers for avapritinib management of PDGFRA D842V-mutant disease and return to regional institutions for routine imatinib or sunitinib monitoring.
Status Page for GIST Care Team Communication
A real-time status page gives GI medical oncologists monitoring imatinib response and sunitinib cardiovascular toxicity, oncology pharmacists reviewing TKI drug-drug interactions and dose modifications, surgical oncologists planning laparoscopic GIST resection, radiologists interpreting Choi criteria CT response assessment, molecular pathologists routing KIT mutation genotyping results, endocrinologists managing sunitinib-induced hypothyroidism, and cardiologists reviewing avapritinib platelet counts and sunitinib LVEF measurements immediate platform visibility without requiring inbound IT support contact. During a TKI management platform outage when a patient's sunitinib cycle is scheduled and a cardiology review is pending, a status page enables the oncology team to activate paper-based HFSR grading and blood pressure monitoring documentation while the platform is restored.
Include the status page URL in imatinib management downtime procedures, sunitinib cardiovascular monitoring contingency workflows, regorafenib hepatotoxicity surveillance emergency protocols, avapritinib platelet safety check fallback procedures, and surgical planning contingency workflows.
Vigilmon Setup for GIST Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | KIT / PDGFRA molecular genotyping | 1 min | Slack + PagerDuty (business hours) | | Imatinib adjuvant and metastatic management | 1 min | Slack + PagerDuty (business hours) | | Sunitinib management and cardiovascular monitoring | 1 min | Slack + PagerDuty (business hours) | | Regorafenib management and hepatotoxicity surveillance | 1 min | Slack + PagerDuty (business hours) | | Avapritinib management and neurological safety | 1 min | Slack + PagerDuty (business hours) | | Ripretinib management | 1 min | Slack + PagerDuty (business hours) | | GIST surgical planning (operative hours) | 1 min | Slack + PagerDuty (surgical hours) | | CT / MRI response assessment (RECIST / Choi) | 1 min | Slack + PagerDuty (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | Long-term adjuvant surveillance imaging | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure KIT and PDGFRA molecular genotyping with immediate business-hours alerting
- Add imatinib management with immediate alerting for toxicity surveillance and dose modification
- Configure sunitinib management with immediate alerting for cardiovascular, thyroid, and hepatotoxicity monitoring
- Add regorafenib management with immediate alerting for hepatotoxicity surveillance (prioritize first 8 weeks of therapy)
- Configure avapritinib management with immediate alerting for platelet count monitoring before each cycle
- Add ripretinib management with immediate business-hours alerting
- Configure GIST surgical planning with immediate alerting during operative and perioperative windows
- Add CT/MRI response assessment with immediate alerting for Choi criteria and RECIST documentation access
- Configure patient communication portal with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, TKI management, molecular genotyping, surgical, and response assessment domains
- Add the status page URL to TKI management downtime procedures, regorafenib hepatotoxicity contingency workflows, and avapritinib platelet safety check fallback protocols
Conclusion
GIST technology platforms are embedded in clinical decisions where KIT and PDGFRA molecular genotyping platform availability at the time of GIST diagnosis determines whether the GI oncologist selecting a first-line therapy for a patient with a gastric GIST can confirm whether the tumor carries an exon 11 KIT deletion — the most imatinib-sensitive variant, responsive to 400 mg/day — or an exon 9 KIT mutation requiring 800 mg/day for adequate kinase inhibition and carrying a meaningfully worse progression-free survival on standard-dose imatinib, or a PDGFRA D842V mutation requiring avapritinib rather than imatinib to achieve the 84% objective response rate that distinguishes the two regimens for this molecularly defined subgroup — a precision that matters only when the genotyping result is accessible at the moment of treatment initiation rather than two weeks later after standard-dose imatinib has already been started on a molecular basis that predicts inadequate tumor control — where sunitinib cardiovascular monitoring platform availability during active second-line therapy for a patient with imatinib-refractory GIST determines whether the oncologist reviewing the echocardiographic report showing a 10% drop in LVEF from baseline can access the sunitinib dose modification algorithm, the prior cardiology consultation notes, and the antihypertensive medication records that together allow a coordinated decision about sunitinib dose interruption, cardiology re-evaluation, and potential resumption at reduced dose — a management sequence that, if delayed by platform inaccessibility, risks progressive cardiac dysfunction in a patient whose sunitinib represents the only approved second-line standard of care — and where avapritinib platelet monitoring platform availability before each treatment cycle for a patient with PDGFRA D842V-mutant GIST determines whether the oncologist can confirm the platelet count result that distinguishes a patient with adequate platelet counts safe to proceed with avapritinib from a patient with Grade 2 thrombocytopenia requiring dose interruption to prevent the intracranial hemorrhage risk that avapritinib's prescribing information specifically warns must be monitored at each cycle through platelet count assessment. A molecular genotyping platform inaccessible when imatinib dose selection requires KIT exon confirmation, a sunitinib cardiovascular monitoring platform unavailable when LVEF decline requires real-time dose modification coordination, an avapritinib safety platform inaccessible before a cycle when platelet count must be confirmed before a drug that carries intracranial hemorrhage warnings — these are not IT incidents. They are clinical disruptions in the management of the paradigmatic molecularly driven sarcoma, where platform availability shapes the molecular precision that determines the therapeutic response to the first drug given, the cardiovascular safety monitoring that enables long-term second-line therapy in patients with GIST-related comorbidities, and the pre-cycle safety checks that prevent life-threatening adverse events in patients treated with targeted agents whose toxicity profiles require continuous, structured, protocol-defined monitoring.
Uptime monitoring gives GIST tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to GI oncology programs, sarcoma specialist centers, molecular genotyping laboratories, and compliance auditors that the platform's operational reliability matches the molecular precision, multi-line TKI management complexity, and continuous safety surveillance demands of modern GIST care.
Start monitoring your GIST tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #GIST #gastrointestinalstromaltumor #imatinib #KITmutation #PDGFRAmutation #D842V #avapritinib #sunitinib #regorafenib #ripretinib #SDHdeficient #molecularlytargeted #tyrosinekinaseinhibitor #Choicriteria #RECIST #GIoncology #softtissuesarcoma #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre